Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Stabilized Nanosponge Particles Sequester and Neutralize Toxins in the Bloodstream

By BiotechDaily International staff writers
Posted on 23 Apr 2013
Print article
Image: Nanosponge Cross Section. Engineers at the University of California, San Diego have invented a "nanosponge" capable of safely removing a broad class of dangerous toxins from the bloodstream, including toxins produced by MRSA (methicillin-resistant Staphylococcus aureus), E Coli, poisonous snakes, and bees. The nanosponges are made of a biocompatible polymer core wrapped in a natural red blood cell membrane (Photo courtesy of Zhang Research Lab, UC San Diego Jacobs School of Engineering).
Image: Nanosponge Cross Section. Engineers at the University of California, San Diego have invented a "nanosponge" capable of safely removing a broad class of dangerous toxins from the bloodstream, including toxins produced by MRSA (methicillin-resistant Staphylococcus aureus), E Coli, poisonous snakes, and bees. The nanosponges are made of a biocompatible polymer core wrapped in a natural red blood cell membrane (Photo courtesy of Zhang Research Lab, UC San Diego Jacobs School of Engineering).
Image: Nanosponge TEM (Transmission electron microscopy) image demonstrated that the nanosponges are approximately 85 nanometers in diameter (Photo courtesy of Zhang Research Lab, UC San Diego Jacobs School of Engineering).
Image: Nanosponge TEM (Transmission electron microscopy) image demonstrated that the nanosponges are approximately 85 nanometers in diameter (Photo courtesy of Zhang Research Lab, UC San Diego Jacobs School of Engineering).
Novel "nanosponges" comprising a biocompatible nanoparticle core coated with fragments of natural red blood cell membranes are able to absorb and neutralize a wide range of pore-forming toxins.

Investigators at the University of California, San Diego (UCSD; USA) had previously used the 85-nanometer diameter nanosponges to deliver chemotherapeutic drugs directly to tumors. The red blood cell membrane coating rendered the nanoparticles invisible to immune system response.

In the current study nanosponges were used to sequester and neutralize toxins circulating in the bloodstream of a mouse model. Results published in the April 14, 2013, online edition of the journal Nature Nanotechnology revealed that preinoculation with nanosponges enabled survival of 89% of mice challenged with a lethal dose of MRSA alpha-hemolysin toxin. Treatment with nanosponges after administration of the lethal dose of toxin resulted in 44% survival. Administering nanosponges and alpha-hemolysin toxin simultaneously at a toxin-to-nanosponge ratio of 70:1 neutralized the toxin and caused no discernible harm to the animals.

In these experiments, the nanosponges were found to have a half-life of 40 hours in the blood circulation of the mice. Eventually the animals' livers metabolized both the nanosponges and the sequestered toxins, with the liver suffering no apparent damage.

"This is a new way to remove toxins from the bloodstream," said senior author Dr. Liangfang Zhang, professor of nanoengineering at UCSD. "Instead of creating specific treatments for individual toxins, we are developing a platform that can neutralize toxins caused by a wide range of pathogens, including MRSA and other antibiotic resistant bacteria."

Related Links:
University of California, San Diego



Print article

Channels

Genomics/Proteomics

view channel
Image: Molecular model of E3 ubiquitin ligase (green), E2 ubiquitin enzyme (orange), \"activated ubiquitin\" (cyan), and \"allosteric ubiquitin\" (blue) (Photo courtesy of Dr. Bernhard Lechtenberg, Sanford Burnham Prebys Medical Discovery Institute).

Researchers Resolve Molecular Structure of Critical Ubiquitin-Binding Enzyme

The molecular structure of a protein complex critically involved in diverse cellular functions such as cell signaling, DNA repair, and mounting anti-inflammatory and immune responses has been elucidated... Read more

Business

view channel

Purchase Agreement to Boost Ebola Vaccine Development

A deal to help boost development of a vaccine to protect against Ebolavirus infection was finalized at the recent Davos Conference in Switzerland. Gavi (Geneva, Switzerland), the global alliance for vaccines and immunizations, announced that it would spend five million USD to purchase the Ebola vaccine under development... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.